Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
AssigneeCentocor, Inc.
InventorsWarren C. Bogard, Jr., Patrick C. Kung
Life of this patent
Estimating the term…
Abstract
Mammalian monoclonal anti-lipopolysaccharide (LPS) antibodies which react with gram-negative bacteria across different genera are disclosed. The anti-LPS antibodies are useful for the treatment or prevention of gram-negative bacteremia and for the detection of gram-negative microorganisms.
Claims3
A human monoclonal antibody which binds to a determinant found in the endotoxin core of gram-negative bacteria wherein said endotoxin core consists essentially of the lipid A and core oligosaccharide regions, and not the O-side chain region of bacterial lipopolysaccharide, and which is cross-reactive with endotoxin from different genera of gram-negative bacteria.
A hybridoma-produced monoclonal antibody which binds to a determinant in the endotoxin core of gram-negative bacteria wherein said endotoxin core consists essentially of the lipid A and core oligosaccharide regions, and not the O-side chain region of bacterial lipopolysaccharide, and which antibody is cross-reactive with endotoxin from different genera of gram-negative bacteria, said monoclonal antibody being produced by a human-human hybridoma.
A hybridoma-produced monoclonal antibody which binds to a determinant in the endotoxin core of gram-negative bacteria wherein said endotoxin core consists essentially of the lipid A and core oligosaccharide regions, and not the O-side chain region of bacterial lipopolysaccharide, and which antibody is cross-reactive with endotoxin from different genera of gram-negative bacteria, said monoclonal antibody being produced by a human-nonhuman hybridoma.
Dependencies are inferred from the claim text.